If you're looking into sermorelin, you may have seen different answers about its regulatory status. Some sources say it's FDA-approved, while others say it isn't. The reality is more complex, and knowing the facts about sermorelin's FDA status can help you make informed choices about your care. Here's what you should know.
The History: Sermorelin was FDA-approved
Sermorelin was originally FDA-approved in the early 1990s under the brand name Geref, manufactured by EMD Serono. It was approved for two purposes: as a diagnostic agent to assess pituitary function and as a treatment for growth hormone deficiency in children. In these approved uses, sermorelin demonstrated both safety and effectiveness in clinical trials that met FDA standards.
The branded product, Geref, was voluntarily discontinued by the manufacturer in 2008. The reason for discontinuation was commercial, not related to safety or efficacy concerns. The manufacturer made a business decision to stop producing the branded product. This is an important distinction because it means Sermorelin wasn't pulled from the market due to problems with the drug itself.
Current Status: Compounded Sermorelin
Today, the sermorelin used in clinical practice is predominantly compounded sermorelin—meaning it's prepared by licensed compounding pharmacies rather than manufactured by a pharmaceutical company with a specific FDA-approved product label. Compounded medications exist in a unique regulatory space. They are legal, widely used, and regulated by both state pharmacy boards and federal guidelines, but they don't carry the same FDA approval as commercially manufactured drugs.
This doesn't mean compounded sermorelin is unregulated. Compounding pharmacies that operate under FDA Section 503A or 503B must follow specific quality standards, including United States Pharmacopeia (USP) guidelines for sterility, potency, and purity. Many also provide certificates of analysis for each batch, detailing the exact composition and quality-testing results.
What This Means for Patients
From a practical standpoint, the regulatory distinction means that when your provider prescribes sermorelin today, they are prescribing a compounded version of a well-studied molecule. The active compound is the same as in the FDA-approved Geref product. The clinical data supporting its use doesn't disappear because the branded version was discontinued. However, the quality of compounded sermorelin depends on the pharmacy that produces it.
This is why choosing the right clinic matters. A reputable provider will source sermorelin from a compounding pharmacy that follows rigorous quality protocols, provides batch-specific certificates of analysis, holds appropriate federal and state licenses, and uses USP-compliant processes for preparation and sterility testing.
Off-Label Use in Adults
It's also worth noting that sermorelin's original FDA approval was for pediatric growth hormone deficiency and diagnostic purposes. The use of sermorelin in adults for age-related growth hormone decline is considered off-label. Off-label prescribing is common and legal in medicine—it simply means a physician uses a medication for a purpose other than what is listed on its original FDA label. Many widely accepted medical treatments started as off-label uses before accumulating enough data to support formal label expansion.
Your provider should be transparent about this aspect of Sermorelin's regulatory status. Off-label use is not inherently risky, but it does mean you should work with a provider who understands the evidence base and appropriately monitors your treatment.
The Regulatory Landscape for Peptides
Sermorelin exists within a broader regulatory conversation about peptides in the United States. The FDA has increased its scrutiny of the compounding industry in recent years, and some peptides have been subject to regulatory changes. As of now, sermorelin remains available through compounding pharmacies and continues to be prescribed by licensed physicians for appropriate clinical uses.
Staying informed about regulatory developments is important. At HRT Wellness, we monitor the regulatory landscape closely and source all of our peptides from licensed, USP-compliant pharmacies. Our medical team can walk you through the specifics of sermorelin's regulatory status and what it means for your treatment. Schedule a consultation to learn more.
Clinical References
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307–308.
- FDA. Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration. Updated 2023.
- United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. USP 2023.